United Therapeutics (UTHR) Revenue (2009 - 2026)

United Therapeutics has disclosed Revenue across 18 years of filings, most recently posting $781.5 million for Q1 2026.

• Revenue for Q1 2026 came in at $781.5 million, down 1.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 5.87% YoY), and the FY2025 annual result was $3.2 billion, up 10.61% from the prior year.
• Revenue came in at $781.5 million for Q1 2026 at United Therapeutics, down from $790.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $799.5 million in Q3 2025 to a low of $461.9 million in Q1 2022.
• The 5-year median for Revenue is $677.7 million (2024), against an average of $653.3 million.
• Across the five-year window, Revenue surged 33.7% in 2024 and slipped 1.62% in 2026, its largest moves.
• United Therapeutics' Revenue stood at $491.5 million in 2022, then grew by 25.07% to $614.7 million in 2023, then climbed by 19.72% to $735.9 million in 2024, then grew by 7.38% to $790.2 million in 2025, then slipped by 1.1% to $781.5 million in 2026.
• The last three Revenue figures came in at $781.5 million (Q1 2026), $790.2 million (Q4 2025), and $799.5 million (Q3 2025), per Business Quant data.